Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kang, H.-J.
Right arrow Articles by Kim, H.-S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kang, H.-J.
Right arrow Articles by Kim, H.-S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Safety and efficacy of intracoronary infusion of mobilized peripheral blood stem cell in patients with myocardial infarction: MAGIC Cell-1 and MAGIC Cell-3-DES-trials

Hyun-Jae Kang1 and Hyo-Soo Kim1,2,*

1 Internal medicine, Seoul National University Hospital, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea
2 National Research Laboratory in Cardiovascular Stem Cell, Seoul, Republic of Korea

* Corresponding author. Tel: +82 2 2072 2226; fax: +82 2 766 8904, E-mail address: hyosoo{at}snu.ac.kr

Previous clinical studies evaluating granulocyte-colony stimulating factor (G-CSF)-based stem-cell therapy showed inconsistent outcomes. We evaluated G-CSF-based stem-cell therapy in patients with acute myocardial infarction (AMI) and old myocardial infarction (OMI) in ‘Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intracoronary Stem Cell Infusion (MAGIC Cell)’ trials. In MAGIC Cell-1 trial, intracoronary infusion of mobilized stem cell by G-CSF is superior to G-CSF alone for improvement of left ventricular (LV) systolic function till 2 years follow-up. In MAGIC Cell-3-Drug eluting stent (DES) trial, cell infusion showed better improvement of LV systolic function and remodelling than control in AMI patients at 6 months follow-up. However, stem-cell therapy does not improve LV systolic function in OMI patients. G-CSF-based stem-cell therapy does not aggravate de novo progression of atherosclerosis while DES efficiently prevents G-CSF-based stem-cell-therapy-related restenosis. Longer-term follow-up is required to confirm prognostic impacts of stem-cell therapy in patients with myocardial infarction. Combination strategy with stem cell therapy with cytokines and genes should be introduced to enhance efficacy of current stem-cell therapy.

Key Words: Myocardial infarction • G-CSF • Peripheral blood stem cell


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.